Summary of Key Information:
Reporting Period (Quarter/Year): Q2 FY27 (Quarter ended September 30, 2026) and H1 FY27 (Six months ended September 30, 2026)
Nature of Filing / Announcement: Outcome of Board Meeting under Regulation 30 and 33 of SEBI LODR Regulations
Audit Opinion:
Clean opinion - Limited review report does not have any modification for both standalone and consolidated financial results.
Key Financial Highlights [₹ crore]:
Standalone Results:
Quarter ended September 30, 2026:
- Revenue from Operations: ₹1,623.46 crore (15.2% increase YoY from ₹1,409.52 crore in Q2 FY26)
- Total Income: ₹1,673.38 crore
- Net Profit: ₹141.44 crore (17.9% decrease YoY from ₹172.31 crore in Q2 FY26)
- EPS: ₹48.04 (from ₹58.53 in Q2 FY26)
- Other Equity: ₹6,324.51 crore (as of September 30, 2026)
- Cash and Cash Equivalents: ₹5.29 crore
- Debt: Short-term borrowings ₹0.96 crore, no significant long-term debt disclosed
Six months ended September 30, 2026:
- Revenue from Operations: ₹3,212.06 crore (18.3% increase YoY from ₹2,714.08 crore)
- Net Profit: ₹342.47 crore (26.8% increase YoY from ₹270.05 crore)
- EPS: ₹116.32 (from ₹91.72)
Consolidated Results:
Quarter ended September 30, 2026:
- Revenue from Operations: ₹1,877.04 crore (21.0% increase YoY from ₹1,551.85 crore in Q2 FY26)
- Total Income: ₹1,925.44 crore
- Net Profit: ₹158.71 crore (13.0% decrease YoY from ₹182.37 crore in Q2 FY26)
- EPS: ₹52.89 (from ₹60.88 in Q2 FY26)
- Other Equity: ₹6,553.61 crore (as of September 30, 2026)
- Cash and Cash Equivalents: ₹85.84 crore
Six months ended September 30, 2026:
- Revenue from Operations: ₹3,724.99 crore (22.9% increase YoY from ₹3,029.85 crore)
- Net Profit: ₹412.64 crore (31.1% increase YoY from ₹314.73 crore)
- EPS: ₹136.21 (from ₹104.28)
Segment-wise Performance [₹ crore]:
Quarter ended September 30, 2026:
- Life Science Chemicals: Revenue ₹427.27 crore, Segment Profit ₹69.68 crore
- Performance and Other Chemicals: Revenue ₹1,503.94 crore, Segment Profit ₹127.83 crore
- Others: Revenue ₹18.90 crore, Segment Loss ₹(0.61) crore
Six months ended September 30, 2026:
- Life Science Chemicals: Revenue ₹896.50 crore, Segment Profit ₹162.46 crore
- Performance and Other Chemicals: Revenue ₹2,931.38 crore, Segment Profit ₹367.66 crore
- Others: Revenue ₹44.88 crore, Segment Profit ₹6.16 crore
Corporate Actions:
Buy-back of shares:
- Approved buyback of up to 1,20,000 fully paid-up Equity Shares (face value ₹10 each)
- Maximum buyback size: ₹90,00,00,000 (₹90 crore) excluding transaction costs
- Maximum buyback price: ₹7,500 per Equity Share
- Represents 0.41% of total outstanding Equity Shares and 1.72% of total paid-up equity share capital and free reserves
- To be executed through open market via NSE and BSE
- Buy-back Committee constituted to oversee the process
Dividend:
- Dividend paid during H1 FY27: ₹88.32 crore (as per cash flow statement)
Other Significant Information:
Balance Sheet Position (Standalone as of September 30, 2026):
- Total Assets: ₹7,711.61 crore
- Total Equity: ₹6,353.97 crore
- Investments: ₹2,151.86 crore (subsidiaries ₹1,235.56 crore + other investments ₹916.30 crore)
- Inventories: ₹891.93 crore
- Trade Receivables: ₹1,259.84 crore
Cash Flow (Standalone H1 FY27):
- Net cash from operating activities: ₹262.22 crore
- Net cash used in investing activities: ₹(179.29) crore
- Net cash used in financing activities: ₹(95.39) crore
Subsidiaries and Associates:
- Consolidated results include 43 subsidiaries, 1 associate, and 2 joint ventures
- 3 subsidiaries reviewed by other auditors with total assets of ₹1,397.34 crore
- 36 subsidiaries not reviewed by their auditors with total assets of ₹336.84 crore